Additionally, a subset of the neoadjuvant population [e.g., patients with HER2-positive or triple-negative breast cancer (TNBC) with high tumor burden] can be used to guide postoperative adjuvant therapy based on the efficacy of neoadjuvant therapy [5]. Here, ERBB2 is linked to neoplasm.